APA

Maes M., Fišar Z., Medina M., Scapagnini G., Nowak G. & Berk M. (20130220). New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. : Inflammopharmacology.

Chicago

Maes Michael, Fišar Zdenĕk, Medina Miguel, Scapagnini Giovanni, Nowak Gabriel and Berk Michael. 20130220. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. : Inflammopharmacology.

Harvard

Maes M., Fišar Z., Medina M., Scapagnini G., Nowak G. and Berk M. (20130220). New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. : Inflammopharmacology.

MLA

Maes Michael, Fišar Zdenĕk, Medina Miguel, Scapagnini Giovanni, Nowak Gabriel and Berk Michael. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. : Inflammopharmacology. 20130220.